{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:14Z","timestamp":1791994574136,"version":"4.4.0"},"reference-count":256,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Pemphigoid diseases constitute a group of organ-specific autoimmune diseases characterized and caused by autoantibodies targeting autoantigens expressed in the skin and mucous membranes. Current therapeutic options are still based on unspecific immunosuppression that is associated with severe adverse events. Biologics, targeting the IL4-pathway or IgE are expected to change the treatment landscape of pemphigoid diseases. However, clinical studies demonstrated that targeting these pathways alone is most likely not sufficient to meet patient and healthcare partitioners expectations. Hence, model systems are needed to identify and validate novel therapeutic targets in pemphigoid diseases. These include pre-clinical animal models,\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>ex vivo<\/jats:italic>\n                    model systems, hypothesis-driven drug repurposing, as well as exploitation of real-world-data. In this review, we will highlight the medical need for pemphigoid diseases, and in-depth discuss the advantages and disadvantages of the available pemphigoid disease model systems. Ultimately, we discuss how rapid translation can be achieved for the benefit of the patients.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1537428","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T01:26:26Z","timestamp":1742174786000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Pemphigoid disease model systems for clinical translation"],"prefix":"10.3389","volume":"16","author":[{"given":"Marvin","family":"Tigges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Dr\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Vorobyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janin","family":"Edelkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.11.014","article-title":"Laminin \u03b24 is a constituent of the cutaneous basement membrane zone and additional autoantigen of anti-p200 pemphigoid","volume":"90","author":"Goletz","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12365189","article-title":"Identification and partial characterization of a novel 105-kDalton lower lamina lucida autoantigen associated with a novel immune-mediated subepidermal blistering disease","volume":"101","author":"Chan","year":"1993","journal-title":"J Invest Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.det.2011.03.013","article-title":"Linear IgA disease: clinical presentation, diagnosis, and pathogenesis","volume":"29","author":"Venning","year":"2011","journal-title":"Dermatologic Clinics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-195302000-00001","article-title":"Pemphigus","volume":"32","author":"Lever","year":"1953","journal-title":"Medicine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17107","article-title":"Incidence of pemphigoid diseases in Northern Germany in 2016 - first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases","volume":"35","author":"van Beek","year":"2021","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20743","article-title":"The global incidence of bullous pemphigoid: a systematic review and meta-analysis","volume":"186","author":"Persson","year":"2022","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(99)70061-7","article-title":"Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence","volume":"41","author":"Jung","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study","volume":"161","author":"Marazza","year":"2009","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2008.06976.x","article-title":"Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany","volume":"7","author":"Bertram","year":"2009","journal-title":"J der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatology: JDDG"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06662.x","article-title":"Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland","volume":"153","author":"Gudi","year":"2005","journal-title":"Br J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ (Clinical Res ed.)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: trigger and predisposing factors","volume":"10","author":"Moro","year":"2020","journal-title":"Biomolecules"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","article-title":"The pathophysiology of bullous pemphigoid","volume":"33","author":"Kasperkiewicz","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000024364","article-title":"Humoral and cellular autoimmunity in autoimmune bullous skin disorders","volume":"122","author":"Hertl","year":"2000","journal-title":"Int Arch Allergy Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00362","article-title":"Epidermolysis bullosa acquisita: the 2019 update","volume":"5","author":"Koga","year":"2019","journal-title":"Front Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.11.029","article-title":"Bullous pemphigoid IgG induces BP180 internalization via a macropinocytic pathway","volume":"182","author":"Hiroyasu","year":"2013","journal-title":"Am J Pathology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1363032","article-title":"State-of-the-art diagnosis of autoimmune blistering diseases","volume":"15","author":"van Beek","year":"2024","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae219","article-title":"Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids","volume":"191","author":"Kridin","year":"2024","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15111","article-title":"Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)","volume":"46","author":"Ujiie","year":"2019","journal-title":"J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00513-3","article-title":"A review comparing international guidelines for the management of bullous pemphigoid, pemphigoid gestationis, mucous membrane pemphigoid, and epidermolysis bullosa acquisita","volume":"21","author":"Patel","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100129","article-title":"How do experts treat patients with bullous pemphigoid around the world? An international survey","volume":"2","author":"Guignant","year":"2022","journal-title":"JID innovations: skin Sci molecules to population Health"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.875492","article-title":"Unmet medical needs in chronic, non-communicable inflammatory skin diseases","volume":"9","author":"Ujiie","year":"2022","journal-title":"Front Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18700","article-title":"Mortality in eight autoimmune bullous diseases: A global large-scale retrospective cohort study","volume":"37","author":"Boch","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereology: JEADV"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany","volume":"136","author":"H\u00fcbner","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00105-017-4089-y","article-title":"Schleimhautpemphigoid","volume":"69","author":"Holtsche","year":"2018","journal-title":"Der Hautarzt"},{"key":"B31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ophtha.2003.03.001","article-title":"Mucous membrane pemphigoid and pseudopemphigoid","volume":"111","author":"Thorne","year":"2004","journal-title":"Ophthalmology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.4773","article-title":"Evaluation of site- and autoantigen-specific characteristics of mucous membrane pemphigoid","volume":"158","author":"van Beek","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/0190-9622(91)70159-y","article-title":"Cicatricial pemphigoid","volume":"24","author":"Ahmed","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116033","article-title":"Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease","volume":"90","author":"Domloge-Hultsch","year":"1992","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.01503.x","article-title":"The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone","volume":"124","author":"Schmidt","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaad.2017.05.016","article-title":"Multiple and repeated sampling increases the sensitivity of direct immunofluorescence testing for the diagnosis of mucous membrane pemphigoid","volume":"77","author":"Shimanovich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14905","article-title":"S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid","volume":"20","author":"Hofmann","year":"2022","journal-title":"J der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatology: JDDG"},{"key":"B39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions","volume":"131","author":"Bernard","year":"1995","journal-title":"Bullous Dis French Study Group Arch Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04919.x","article-title":"Spectrum of subepidermal immunobullous disorders seen at the National Skin Centre, Singapore: a 2-year review","volume":"147","author":"Wong","year":"2002","journal-title":"Br J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2003.tb00376.x","article-title":"Epidermolysis bullosa acquisita in childhood","volume":"30","author":"Trigo-Guzm\u00e1n","year":"2003","journal-title":"J Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12011","article-title":"Diagnosis and disease severity assessment of epidermolysis bullosa acquisita by ELISA for anti-type VII collagen autoantibodies: an Italian multicentre study","volume":"168","author":"Marzano","year":"2013","journal-title":"Br J Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-018-0896-1","article-title":"Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients","volume":"13","author":"Iwata","year":"2018","journal-title":"Orphanet J Rare Diseases"},{"key":"B44","doi-asserted-by":"publisher","first-page":"79s","DOI":"10.1111\/1523-1747.ep12275505","article-title":"Epidermolysis bullosa acquisita of the immunopathological type (dermolytic pemphigoid)","volume":"85","author":"Briggaman","year":"1985","journal-title":"J Invest Dermatol"},{"key":"B45","article-title":"Epidermolysis bullosa acquisita","volume":"7","author":"Gammon","year":"1988","journal-title":"Semin Dermatol"},{"key":"B46","article-title":"Review and update of epidermolysis bullosa acquisita","volume":"7","author":"Woodley","year":"1988","journal-title":"Semin Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bjd.16138","article-title":"International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita","volume":"179","author":"Prost-Squarcioni","year":"2018","journal-title":"Br J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/1523-1747.ep12285634","article-title":"Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita","volume":"108","author":"Chen","year":"1997","journal-title":"J Invest Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/08916934.2011.606450","article-title":"Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen","volume":"45","author":"Chen","year":"2012","journal-title":"Autoimmunity"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10346.x","article-title":"The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy","volume":"165","author":"Buijsrogge","year":"2011","journal-title":"Br J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06006.x","article-title":"U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases","volume":"151","author":"Vodegel","year":"2004","journal-title":"Br J Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1065","article-title":"Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases","volume":"91","author":"Kim","year":"2011","journal-title":"Acta Dermato-Venereologica"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02466","article-title":"Anti-p200 pemphigoid: A systematic review","volume":"10","author":"Kridin","year":"2019","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.02.036","article-title":"Anti-p200 pemphigoid","volume":"71","author":"Goletz","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.1999.00472.x","article-title":"Clinical features and management of 87 patients with pemphigoid gestationis","volume":"24","author":"Jenkins","year":"1999","journal-title":"Clin Exp Dermatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2005.12.012","article-title":"The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients","volume":"54","author":"Ambros-Rudolph","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.604945","article-title":"A systematic review of treatment options and clinical outcomes in pemphigoid gestationis","volume":"7","author":"Genovese","year":"2020","journal-title":"Front Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.05.087","article-title":"Pemphigoid gestationis is associated with an increased risk for adverse pregnancy outcomes: A large-scale propensity-matched retrospective cohort study","volume":"91","author":"Preu\u00df","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18973","article-title":"Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationis","volume":"37","author":"Cordel","year":"2023","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S128144","article-title":"Pemphigoid gestationis: current perspectives","volume":"10","author":"S\u00e4vervall","year":"2017","journal-title":"Clinical Cosmetic Investigational Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.det.2011.03.002","article-title":"Pemphigoid gestationis: pathogenesis and clinical features","volume":"29","author":"Intong","year":"2011","journal-title":"Dermatologic Clinics"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2004.01481.x","article-title":"Maternal and neonatal pemphigoid gestationis","volume":"29","author":"Al-Mutairi","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"B63","unstructured":"Linear IGA dermatosis\n          \n          \n            \n              Bernett\n              CN\n            \n            \n              Fong\n              M\n            \n            \n              Yadlapati\n              S\n            \n            \n              Rosario-Collazo\n              JA\n            \n          \n          Treasure Island (FL\n          StatPearls Publishing\n          StatPearls\n          \n          2024"},{"key":"B64","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/s0190-9622(88)70236-4","article-title":"Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap","volume":"19","author":"Wojnarowska","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114508","article-title":"Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis","volume":"85","author":"Zone","year":"1990","journal-title":"J Clin Invest"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12345782","article-title":"LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells","volume":"106","author":"Marinkovich","year":"1996","journal-title":"J Invest Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-019-4377-9","article-title":"Lineare igA-dermatose","volume":"70","author":"Juratli","year":"2019","journal-title":"Der Hautarzt"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57080818","article-title":"Updates in the diagnosis and management of linear igA disease: A systematic review","volume":"57","author":"Shin","year":"2021","journal-title":"Medicina (Kaunas Lithuania)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.937528","article-title":"Linear immunoglobulin a bullous dermatosis in children","volume":"10","author":"Mori","year":"2022","journal-title":"Front Pediatrics"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.737813","article-title":"Lichen planus","volume":"8","author":"Boch","year":"2021","journal-title":"Front Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01389","article-title":"Lichen planus pemphigoides: from lichenoid inflammation to autoantibody-mediated blistering","volume":"10","author":"H\u00fcbner","year":"2019","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10413.x","article-title":"Mortality of bullous pemphigoid in Switzerland: a prospective study","volume":"165","author":"Cort\u00e9s","year":"2011","journal-title":"Br J Dermatol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.2340\/00015555-3400","article-title":"Drug development in pemphigoid diseases","volume":"100","author":"Bieber","year":"2020","journal-title":"Acta Dermato-Venereologica"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.7.903","article-title":"Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age","volume":"138","author":"Rzany","year":"2002","journal-title":"Arch Dermatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: A review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17397","article-title":"European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I","volume":"35","author":"Rashid","year":"2021","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17395","article-title":"European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II","volume":"35","author":"Schmidt","year":"2021","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19880","article-title":"S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology","volume":"38","author":"Caux","year":"2024","journal-title":"J Eur Acad Dermatol Venereology"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3052","article-title":"Unmet needs in pemphigoid diseases: an international survey amongst patients, clinicians and researchers","volume":"99","author":"Lamberts","year":"2019","journal-title":"Acta Dermato Venereologica"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.12.001","article-title":"Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII","volume":"73","author":"Nishie","year":"2014","journal-title":"J Dermatol Science"},{"key":"B82","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/JID.2015.356","article-title":"Epidermolysis bullosa acquisita: from pathophysiology to novel therapeutic options","volume":"136","author":"Kasperkiewicz","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13415","article-title":"In vitro and in vivo models to investigate the pathomechanisms and novel treatments for pemphigoid diseases","volume":"26","author":"Bieber","year":"2017","journal-title":"Exp Dermatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13335","article-title":"Signalling and targeted therapy of inflammatory cells in epidermolysis bullosa acquisita","volume":"26","author":"Ludwig","year":"2017","journal-title":"Exp Dermatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/s0738-081x(00)00197-8","article-title":"Autoimmune blistering dermatoses in domestic animals","volume":"19","author":"Olivry","year":"2001","journal-title":"Clinics Dermatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.443","article-title":"Deletion of the major bullous pemphigoid epitope region of collagen XVII induces blistering, autoimmunization, and itching in mice","volume":"135","author":"Hurskainen","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116856","article-title":"A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180","volume":"92","author":"Liu","year":"1993","journal-title":"J Clin Invest"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031066","article-title":"The flavonoid luteolin inhibits Fc\u03b3-dependent respiratory burst in granulocytes, but not skin blistering in a new model of pemphigoid in adult mice","volume":"7","author":"Oswald","year":"2012","journal-title":"PloS One"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2014.05.007","article-title":"Fc\u03b3 receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid","volume":"184","author":"Schulze","year":"2014","journal-title":"Am J Pathology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/nm1496","article-title":"Humanization of autoantigen","volume":"13","author":"Nishie","year":"2007","journal-title":"Nat Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2008.08.009","article-title":"Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model","volume":"31","author":"Liu","year":"2008","journal-title":"J Autoimmunity"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01558","article-title":"Therapeutic effect of a novel phosphatidylinositol-3-kinase \u03b4 Inhibitor in experimental epidermolysis bullosa acquisita","volume":"9","author":"Koga","year":"2018","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/biom12101461","article-title":"Anti-laminin 332-type mucous membrane pemphigoid","volume":"12","author":"Shi","year":"2022","journal-title":"Biomolecules"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150316122502","article-title":"Animal models to investigate pathomechanisms and evaluate novel treatments for autoimmune bullous dermatoses","volume":"21","author":"Iwata","year":"2015","journal-title":"Curr Pharm Design"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/path.4556","article-title":"The retinoid-related orphan receptor alpha is essential for the end-stage effector phase of experimental epidermolysis bullosa acquisita","volume":"237","author":"Sadeghi","year":"2015","journal-title":"J Pathology"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/JID.2015.361","article-title":"Dimethylfumarate impairs neutrophil functions","volume":"136","author":"M\u00fcller","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.128239","article-title":"Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease","volume":"4","author":"Sezin","year":"2019","journal-title":"JCI Insight"},{"key":"B98","unstructured":"EU\/3\/16\/1698 - orphan designation for treatment of bullous pemphigoid\n          \n          European Medicines Agency (EMA"},{"key":"B99","unstructured":"EU\/3\/20\/2289 - orphan designation for treatment of bullous pemphigoid\n          \n          European Medicines Agency (EMA"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1156","article-title":"Evaluation of nomacopan for treatment of bullous pemphigoid: A phase 2a nonrandomized controlled trial","volume":"158","author":"Sadik","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.865241","article-title":"Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases","volume":"13","author":"Ghorbanalipoor","year":"2022","journal-title":"Front Immunol"},{"key":"B102","unstructured":"Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and\/or oral mucous membrane pemphigoid\n          \n          \n            \n              Schmidt\n              E\n            \n            \n              Ludwig\n              R\n            \n            \n              Patzelt\n              S\n            \n            \n              Aramini\n              A\n            \n            \n              Brandolini\n              L\n            \n            \n              Cocchiaro\n              P\n            \n          \n          \n          2024"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1172\/JCI8748","article-title":"Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus","volume":"105","author":"Amagai","year":"2000","journal-title":"J Clin Invest"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903101","article-title":"A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen","volume":"184","author":"Ujiie","year":"2010","journal-title":"J Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.10.002","article-title":"Noncollagenous 16A domain of type XVII collagen-reactive CD4+ T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model","volume":"142","author":"Ujiie","year":"2012","journal-title":"Clin Immunol (Orlando Fla.)"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.005","article-title":"Intravenous igG reduces pathogenic autoantibodies, serum IL-6 levels, and disease severity in experimental bullous pemphigoid models","volume":"138","author":"Sasaoka","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.5.3461","article-title":"Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice1","volume":"177","author":"Sitaru","year":"2006","journal-title":"J Immunol (Baltimore Md. : 1950)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100596","article-title":"Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice","volume":"187","author":"Hirose","year":"2011","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300310","article-title":"B cells, dendritic cells, and macrophages are required to induce an autoreactive CD4 helper T cell response in experimental epidermolysis bullosa acquisita","volume":"191","author":"Iwata","year":"2013","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.08.030","article-title":"The anti-C1s antibody TNT003 prevents complement activation in the skin induced by bullous pemphigoid autoantibodies","volume":"138","author":"Kasprick","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.619","article-title":"PDE4 inhibition as potential treatment of epidermolysis bullosa acquisita","volume":"136","author":"Koga","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13439","article-title":"Evidence for a contributory role of a xenogeneic immune response in experimental epidermolysis bullosa acquisita","volume":"26","author":"Niebuhr","year":"2017","journal-title":"Exp Dermatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2019.02.001","article-title":"Successful management of bullous pemphigoid with dimethyl fumarate therapy: A case report","volume":"5","author":"Bilgic-Temel","year":"2019","journal-title":"Int J Women\u2019s Dermatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2862","article-title":"Galactosylated IgG1 links Fc\u03b3RIIB and Dectin-1 to block complement-mediated inflammation","volume":"18","author":"Karsten","year":"2012","journal-title":"Nat Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.12.021","article-title":"The leukotriene B4 and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita","volume":"137","author":"Sezin","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00535","article-title":"Specific inhibition of complement activation significantly ameliorates autoimmune blistering disease in mice","volume":"9","author":"Mihai","year":"2018","journal-title":"Front Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"ra23","DOI":"10.1126\/scisignal.2001617","article-title":"PI3K\u03b2 plays a critical role in neutrophil activation by immune complexes","volume":"4","author":"Kulkarni","year":"2011","journal-title":"Sci Signaling"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.713312","article-title":"Topical application of the PI3K\u03b2-selective small molecule inhibitor TGX-221 is an effective treatment option for experimental epidermolysis bullosa acquisita","volume":"8","author":"Zillikens","year":"2021","journal-title":"Front Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1957874","article-title":"Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K \u03b2\/\u03b4 in relapsed refractory B cell lymphoma","volume":"62","author":"Nastoupil","year":"2021","journal-title":"Leukemia Lymphoma"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13027","article-title":"Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase \u03b2 inhibition and aspirin in man","volume":"13","author":"Nylander","year":"2015","journal-title":"J Thromb haemostasis: JTH"},{"key":"B121","unstructured":"Commission acts to accelerate phasing out of animal testing"},{"key":"B122","article-title":"Russell and Burch\u2019s 3Rs then and now: the need for clarity in definition and purpose","volume":"54","author":"Tannenbaum","year":"2015","journal-title":"J Am Assoc Lab Anim Science: JAALAS"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103302","article-title":"High throughput screening identifies repurposable drugs for modulation of innate and acquired immune responses","volume":"148","author":"Ghorbanalipoor","year":"2024","journal-title":"J Autoimmunity"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101638","article-title":"Strategic focus on 3R principles reveals major reductions in the use of animals in pharmaceutical toxicity testing","volume":"9","author":"T\u00f6rnqvist","year":"2014","journal-title":"PloS One"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18441","article-title":"Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study","volume":"36","author":"Bardazzi","year":"2022","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.immuni.2024.08.005","article-title":"Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases","volume":"57","author":"Saggau","year":"2024","journal-title":"Immunity"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.2015","article-title":"Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230","volume":"176","author":"Thoma-Uszynski","year":"2006","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-00467-0","article-title":"Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity","volume":"16","author":"Kiesgen","year":"2021","journal-title":"Nat Protoc"},{"key":"B129","doi-asserted-by":"publisher","first-page":"18991","DOI":"10.1038\/s41598-019-54421-6","article-title":"Author Correction: B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid","volume":"9","author":"Berkani","year":"2019","journal-title":"Sci Rep"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/antib13040081","article-title":"Measurement of the memory B cell response via antibodies from activated cells","volume":"13","author":"Rockstroh","year":"2024","journal-title":"Antibodies (Basel Switzerland)"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"B134","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41467-018-03061-x","article-title":"A human endothelial cell-based recycling assay for screening of FcRn targeted molecules","volume":"9","author":"Grevys","year":"2018","journal-title":"Nat Commun"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1144429","article-title":"Adaptive and innate immune pathogenesis of bullous pemphigoid: A review","volume":"14","author":"Yan","year":"2023","journal-title":"Front Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00141.x","article-title":"Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes","volume":"115","author":"Schmidt","year":"2000","journal-title":"J Invest Dermatol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment","volume":"129","author":"Iwata","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0136-2","article-title":"Gestational pemphigoid","volume":"9","author":"Huilaja","year":"2014","journal-title":"Orphanet J Rare Diseases"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18156","article-title":"Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low-molecular-weight heparin tinzaparin sodium","volume":"181","author":"Gutjahr","year":"2019","journal-title":"Br J Dermatol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/j.jid.2019.04.025","article-title":"Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal-epidermal junction in bullous pemphigoid","volume":"139","author":"Freire","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.02.001","article-title":"C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement","volume":"32","author":"Liu","year":"2024","journal-title":"Mol Therapy: J Am Soc Gene Ther"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.230","article-title":"Fc\u03b3RIIA and Fc\u03b3RIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous pemphigoid","volume":"130","author":"Yu","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.06.006","article-title":"The neutrophil","volume":"54","author":"Burn","year":"2021","journal-title":"Immunity"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1002\/prca.202300233","article-title":"Methods and clinical biomarker discovery for targeted proteomics using Olink technology","volume":"18","author":"Wang","year":"2024","journal-title":"Proteomics. Clin Applications"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-022-00830-7","article-title":"High-throughput proteomics: a methodological mini-review","volume":"102","author":"Cui","year":"2022","journal-title":"Lab Investigation; J Tech Methods Pathology"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/cpph.55","article-title":"Drug discovery for pemphigoid diseases","volume":"84","author":"Kasprick","year":"2019","journal-title":"Curr Protoc Pharmacol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400160","article-title":"Recombinant human IgA1 and IgA2 autoantibodies to type VII collagen induce subepidermal blistering ex vivo","volume":"193","author":"Recke","year":"2014","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1136\/adc.66.1.115","article-title":"Field trials of the Baby Check score card in hospital","volume":"66","author":"Thornton","year":"1991","journal-title":"Arch Dis Childhood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/path.2157","article-title":"NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage","volume":"212","author":"Chiriac","year":"2007","journal-title":"J Pathology"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/path.1674","article-title":"Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid","volume":"204","author":"Shimanovich","year":"2004","journal-title":"J Pathology"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.05.013","article-title":"Neonatal fc receptor inhibition reduces bullous pemphigoid anti-basement membrane zone igG deposition and blistering in 3-dimensional human skin equivalents","volume":"144","author":"Bao","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B152","unstructured":"Real-world evidence\n          \n          FDA"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104888","article-title":"A pancreatic cancer risk prediction model (Prism) developed and validated on large-scale US clinical data","volume":"98","author":"Jia","year":"2023","journal-title":"EBioMedicine"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab: the first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"Grillo-L\u00f3pez","year":"2000","journal-title":"Curr Pharm Biotechnol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet (London England)"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"New Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915205","article-title":"Rituximab therapy for mucous membrane pemphigoid: A retrospective monocentric study with long-term follow-up in 109 patients","volume":"13","author":"Bohelay","year":"2022","journal-title":"Front Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients","volume":"81","author":"Polansky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03889.x","article-title":"Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients","volume":"25","author":"Lourari","year":"2011","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"New Engl J Med"},{"key":"B162","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet (London England)"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1203776","article-title":"Skin-infiltrating T cells display distinct inflammatory signatures in lichen planus, bullous pemphigoid and pemphigus vulgaris","volume":"14","author":"Schinner","year":"2023","journal-title":"Front Immunol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"13030\/qt25q9w6r9","DOI":"10.5070\/D32511046147","article-title":"Dupilumab for bullous pemphigoid with intractable pruritus","volume":"25","author":"Seidman","year":"2019","journal-title":"Dermatol Online J"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae403","article-title":"Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicenter case series","volume":"192","author":"Planella-Fontanillas","year":"2024","journal-title":"Br J Dermatol"},{"key":"B167","unstructured":"Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad331","article-title":"Rapid and sustained response to tralokinumab in a patient with severe bullous pemphigoid and end-stage kidney disease","volume":"49","author":"Maglie","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"ljaf035","DOI":"10.1093\/bjd\/ljaf035","article-title":"Off-label use of tralokinumab in the treatment of bullous pemphigoid- a case series","volume":"29","author":"Maglie","year":"2025","journal-title":"Br J Dermatol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"New Engl J Med"},{"key":"B173","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"New Engl J Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid","volume":"138","author":"Lin","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8547-7","article-title":"Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid","volume":"59","author":"Messingham","year":"2014","journal-title":"Immunologic Res"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab","volume":"123","author":"Fairley","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad369","article-title":"Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients","volume":"190","author":"Chebani","year":"2024","journal-title":"Br J Dermatol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874108","article-title":"Rapid disease control in first-line therapy-resistant mucous membrane pemphigoid and bullous pemphigoid with omalizumab as add-on therapy: A case series of 13 patients","volume":"13","author":"Alexandre","year":"2022","journal-title":"Front Immunol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet (London England)"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"New Engl J Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6716419","article-title":"Expression of the JAK\/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Juczynska","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(87)90805-2","article-title":"A new paraspinal window in the echocardiographic diagnosis of descending aortic dissection","volume":"114","author":"Klein","year":"1987","journal-title":"Am Heart J"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101104","article-title":"Tofacitinib for refractory ocular mucous membrane pemphigoid","volume":"22","author":"James","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14345","article-title":"Successful treatment of infantile refractory bullous pemphigoid with baricitinib","volume":"65","author":"Zhou","year":"2024","journal-title":"Australas J Dermatol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2302394","article-title":"Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review","volume":"35","author":"Su","year":"2024","journal-title":"J Dermatol Treat"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110591","article-title":"Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature","volume":"122","author":"Li","year":"2023","journal-title":"Int Immunopharmacology"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.12.006","article-title":"Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib","volume":"32","author":"Nash","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B190","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdcr.2022.10.028","article-title":"Two cases of bullous pemphigoid effectively treated with oral tofacitinib","volume":"32","author":"Youssef","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S451007","article-title":"Real-time experience of abrocitinib for the treatment of mucous membrane pemphigoid: A case report","volume":"18","author":"Teng","year":"2024","journal-title":"Patient Preference Adherence"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.07.013","article-title":"Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate","volume":"27","author":"Burningham","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17472","article-title":"A successful experience in treating lichen planus pemphigoides with tofacitinib: a case report","author":"Balighi","year":"2024","journal-title":"Int J Dermatol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20094","article-title":"Differing features of pemphigus in skin of colour versus white skin: A broad-scale cohort study","volume":"39","author":"Kasperkiewicz","year":"2025","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(94)70227-6","article-title":"Low-dose methotrexate treatment in elderly patients with bullous pemphigoid","volume":"31","author":"Paul","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"B196","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/j.annder.2017.09.087","article-title":"Corticoth\u00e9rapie locale br\u00e8ve + m\u00e9thotrexate vs corticoth\u00e9rapie locale seule prolong\u00e9e dans la pemphigo\u00efde bulleuse: essai national multicentrique","volume":"144","author":"Dereure","year":"2017","journal-title":"Annales Dermatologie V\u00e9n\u00e9r\u00e9ologie"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1354\/vp.36-4-328","article-title":"Novel feline autoimmune blistering disease resembling bullous pemphigoid in humans: IgG autoantibodies target the NC16A ectodomain of type XVII collagen (BP180\/BPAG2)","volume":"36","author":"Olivry","year":"1999","journal-title":"Veterinary Pathology"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1177\/030098589503200407","article-title":"Canine bullous pemphigoid (BP): identification of the 180-kd canine BP antigen by circulating autoantibodies","volume":"32","author":"Iwasaki","year":"1995","journal-title":"Veterinary Pathology"},{"key":"B199","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/s0925-4439(99)00092-7","article-title":"Molecular cloning of canine bullous pemphigoid antigen 2 cDNA and immunomapping of NC16A domain by canine bullous pemphigoid autoantibodies","volume":"1500","author":"Xu","year":"2000","journal-title":"Biochim Et Biophys Acta"},{"key":"B200","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/pl00007459","article-title":"A spontaneously arising porcine model of bullous pemphigoid","volume":"292","author":"Olivry","year":"2000","journal-title":"Arch Dermatol Res"},{"key":"B201","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s0165-2427(99)00151-8","article-title":"Equine bullous pemphigoid IgG autoantibodies target linear epitopes in the NC16A ectodomain of collagen XVII (BP180, BPAG2)","volume":"73","author":"Olivry","year":"2000","journal-title":"Veterinary Immunol Immunopathology"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.2001.0510","article-title":"A spontaneous canine model of mucous membrane (cicatricial) pemphigoid, an autoimmune blistering disease affecting mucosae and mucocutaneous junctions","volume":"16","author":"Olivry","year":"2001","journal-title":"J Autoimmunity"},{"key":"B203","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/vde.12255","article-title":"Canine epidermolysis bullosa acquisita: a retrospective study of 20 cases","volume":"26","author":"Bizikova","year":"2015","journal-title":"Veterinary Dermatol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-17","article-title":"Passive transfer of collagen XVII-specific antibodies induces sustained blistering disease in adult mice","volume":"8","author":"Chiriac","year":"2013","journal-title":"Orphanet J Rare Diseases"},{"key":"B205","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.jaci.2018.04.006","article-title":"Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease","volume":"142","author":"Haeberle","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1002\/path.6220","article-title":"Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A\/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade","volume":"262","author":"Pigors","year":"2024","journal-title":"J Pathology"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000667","article-title":"Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model","volume":"185","author":"Li","year":"2010","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21386","article-title":"Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen","volume":"115","author":"Sitaru","year":"2005","journal-title":"J Clin Invest"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23702.x","article-title":"Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita","volume":"124","author":"Woodley","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.061212","article-title":"The cartilage matrix protein subdomain of type VII collagen is pathogenic for epidermolysis bullosa acquisita","volume":"170","author":"Chen","year":"2007","journal-title":"Am J Pathology"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12338","article-title":"Blister-inducing antibodies target multiple epitopes on collagen VII in mice","volume":"18","author":"Csorba","year":"2014","journal-title":"J Cell Mol Med"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501003","article-title":"Radiosensitive hematopoietic cells determine the extent of skin inflammation in experimental epidermolysis bullosa acquisita","volume":"195","author":"Iwata","year":"2015","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1038\/srep38357","article-title":"T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita","volume":"6","author":"Bieber","year":"2016","journal-title":"Sci Rep"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.51","article-title":"Autoantibodies to multiple epitopes on the non-collagenous-1 domain of type VII collagen induce blisters","volume":"135","author":"Vorobyev","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118942","article-title":"Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice","volume":"98","author":"Lazarova","year":"1996","journal-title":"J Clin Invest"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.03.037","article-title":"Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological characteristics of the human disease","volume":"137","author":"Heppe","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00829.x","article-title":"Human anti-laminin 5 autoantibodies induce subepidermal blisters in an experimental human skin graft model","volume":"114","author":"Lazarova","year":"2000","journal-title":"J Invest Dermatol"},{"key":"B218","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1087-0024.2004.00840.x","article-title":"IgA autoimmune disorders: development of a passive transfer mouse model","volume":"9","author":"Zone","year":"2004","journal-title":"J Invest Dermatol Symposium Proc"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2015.12.001","article-title":"Myeloid-related proteins-8 and -14 are expressed but dispensable in the pathogenesis of experimental epidermolysis bullosa acquisita and bullous pemphigoid","volume":"81","author":"Akbarzadeh","year":"2016","journal-title":"J Dermatol Science"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.05.016","article-title":"Increased TREM-1 expression in inflamed skin has no functional impact on the pathogenesis of cutaneous disorders","volume":"88","author":"Dr\u00e4ger","year":"2017","journal-title":"J Dermatol Science"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.06.019","article-title":"CCL3\/MIP1\u03b1 represents a biomarker but not a mandatory cytokine for disease development in experimental epidermolysis bullosa acquisita","volume":"88","author":"Kasperkiewicz","year":"2017","journal-title":"J Dermatol Science"},{"key":"B222","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J Clin Invest"},{"key":"B223","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2012.08.002","article-title":"Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction","volume":"40","author":"Samavedam","year":"2013","journal-title":"J Autoimmunity"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23977","article-title":"Synergy between a plasminogen cascade and MMP-9 in autoimmune disease","volume":"115","author":"Liu","year":"2005","journal-title":"J Clin Invest"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.877958","article-title":"Pathological relevance of anti-hsp70 igG autoantibodies in epidermolysis bullosa acquisita","volume":"13","author":"Tukaj","year":"2022","journal-title":"Front Immunol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00488","article-title":"Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2","volume":"9","author":"Karsten","year":"2018","journal-title":"Front Immunol"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402688","article-title":"Caspase-1-independent IL-1 release mediates blister formation in autoantibody-induced tissue injury through modulation of endothelial adhesion molecules","volume":"194","author":"Sadeghi","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"B228","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/path.4023","article-title":"Genetic identification and functional validation of Fc\u03b3RIV as key molecule in autoantibody-induced tissue injury","volume":"228","author":"Kasperkiewicz","year":"2012","journal-title":"J Pathology"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.10.6514","article-title":"The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita","volume":"178","author":"Mihai","year":"2007","journal-title":"J Immunol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13434","article-title":"CD11b-deficient mice exhibit an increased severity in the late phase of antibody transfer-induced experimental epidermolysis bullosa acquisita","volume":"26","author":"Deng","year":"2017","journal-title":"Exp Dermatol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2015.00206","article-title":"Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment","volume":"22","author":"Hirose","year":"2017","journal-title":"Mol Med (Cambridge Mass.)"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1002\/path.2973","article-title":"Overexpression of the Flii gene increases dermal-epidermal blistering in an autoimmune ColVII mouse model of epidermolysis bullosa acquisita","volume":"225","author":"Kopecki","year":"2011","journal-title":"J Pathology"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.457","article-title":"Topically applied flightless I neutralizing antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita","volume":"133","author":"Kopecki","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1343299","article-title":"Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita","volume":"15","author":"Gross","year":"2024","journal-title":"Front Immunol"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.451","article-title":"Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita","volume":"135","author":"Iwata","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.91","article-title":"Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation","volume":"133","author":"Hellberg","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B237","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41467-020-20604-3","article-title":"Granzyme B inhibition reduces disease severity in autoimmune blistering diseases","volume":"12","author":"Hiroyasu","year":"2021","journal-title":"Nat Commun"},{"key":"B238","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.jid.2021.12.029","article-title":"C5aR2 deficiency ameliorates inflammation in murine epidermolysis bullosa acquisita by regulating fc\u03b3 Receptor expression on neutrophils","volume":"142","author":"Seiler","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1197709","article-title":"The complement receptor C5aR2 regulates neutrophil activation and function contributing to neutrophil-driven epidermolysis bullosa acquisita","volume":"14","author":"Seiler","year":"2023","journal-title":"Front Immunol"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750160","article-title":"Preventive but not therapeutic topical application of local anesthetics can inhibit experimental epidermolysis bullosa acquisita in mice","volume":"12","author":"Wen","year":"2021","journal-title":"Front Immunol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.04.025","article-title":"Propranolol is an effective topical and systemic treatment option for experimental epidermolysis bullosa acquisita","volume":"140","author":"St\u00fcssel","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7412.S3-005","article-title":"The allosteric CXCR1\/2 inhibitor DF2156A improves experimental epidermolysis bullosa acquisita","author":"Hirose","year":"2013","journal-title":"Genet Syndromes Gene Ther"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11004","article-title":"Neutrophil-specific deletion of the CARD9 gene expression regulator suppresses autoantibody-induced inflammation in vivo","volume":"7","author":"N\u00e9meth","year":"2016","journal-title":"Nat Commun"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.938306","article-title":"Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita","volume":"13","author":"Haeger","year":"2022","journal-title":"Front Immunol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00249","article-title":"Whole-genome expression profiling in skin reveals SYK as a key regulator of inflammation in experimental epidermolysis bullosa acquisita","volume":"9","author":"Samavedam","year":"2018","journal-title":"Front Immunol"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.12.016","article-title":"Neutrophil-specific syk expression is crucial for skin disease in experimental epidermolysis bullosa acquisita","volume":"143","author":"N\u00e9meth","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.017","article-title":"The syk tyrosine kinase is required for skin inflammation in an in vivo mouse model of epidermolysis bullosa acquisita","volume":"137","author":"N\u00e9meth","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2012.04.002","article-title":"Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen","volume":"39","author":"Hirose","year":"2012","journal-title":"J Autoimmunity"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314609","article-title":"Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets","volume":"117","author":"Kasperkiewicz","year":"2011","journal-title":"Blood"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.09.009","article-title":"Calcitriol treatment ameliorates inflammation and blistering in mouse models of epidermolysis bullosa acquisita","volume":"138","author":"Tukaj","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.09.019","article-title":"Phospholipase C\u03b32 is essential for experimental models of epidermolysis bullosa acquisita","volume":"142","author":"Szilveszter","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301556","article-title":"GM-CSF modulates autoantibody production and skin blistering in experimental epidermolysis bullosa acquisita","volume":"192","author":"Samavedam","year":"2014","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid","volume":"96","author":"Chakievska","year":"2019","journal-title":"J Autoimmunity"},{"key":"B254","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1084\/jem.20132496","article-title":"The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment","volume":"211","author":"Kov\u00e1cs","year":"2014","journal-title":"J Exp Med"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-008-0366-7","article-title":"Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita","volume":"86","author":"Sesarman","year":"2008","journal-title":"J Mol Med (Berlin Germany)"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.3.475","article-title":"Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid","volume":"188","author":"Liu","year":"1998","journal-title":"J Exp Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1537428\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T01:26:36Z","timestamp":1742174796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1537428\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":256,"alternative-id":["10.3389\/fimmu.2025.1537428"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1537428","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"article-number":"1537428"}}